Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Free Cash Flow (2016 - 2025)

vTv Therapeutics' Free Cash Flow history spans 12 years, with the latest figure at -$9.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 91.73% year-over-year to -$9.3 million; the TTM value through Dec 2025 reached -$25.3 million, changed 0.21%, while the annual FY2025 figure was -$25.3 million, 0.21% changed from the prior year.
  • Free Cash Flow for Q4 2025 was -$9.3 million at vTv Therapeutics, down from -$5.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $706000.0 in Q2 2022 and bottomed at -$9.3 million in Q4 2025.
  • The 5-year median for Free Cash Flow is -$5.3 million (2021), against an average of -$5.2 million.
  • The largest annual shift saw Free Cash Flow soared 117.66% in 2022 before it tumbled 973.51% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$6.4 million in 2021, then fell by 7.22% to -$6.9 million in 2022, then surged by 57.65% to -$2.9 million in 2023, then plummeted by 65.58% to -$4.8 million in 2024, then plummeted by 91.73% to -$9.3 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Free Cash Flow are -$9.3 million (Q4 2025), -$5.2 million (Q3 2025), and -$5.1 million (Q2 2025).